TNXP vs. CELU, VHAQ, MNOV, RLYB, CKPT, AFMD, MURA, IMMX, THTX, and LPTX
Should you be buying Tonix Pharmaceuticals stock or one of its competitors? The main competitors of Tonix Pharmaceuticals include Celularity (CELU), Viveon Health Acquisition (VHAQ), MediciNova (MNOV), Rallybio (RLYB), Checkpoint Therapeutics (CKPT), Affimed (AFMD), Mural Oncology (MURA), Immix Biopharma (IMMX), Theratechnologies (THTX), and Leap Therapeutics (LPTX). These companies are all part of the "pharmaceutical preparations" industry.
Tonix Pharmaceuticals (NASDAQ:TNXP) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.
Celularity has higher revenue and earnings than Tonix Pharmaceuticals.
Tonix Pharmaceuticals has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500. Comparatively, Celularity has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.
82.3% of Tonix Pharmaceuticals shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 0.5% of Tonix Pharmaceuticals shares are held by company insiders. Comparatively, 20.7% of Celularity shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Tonix Pharmaceuticals presently has a consensus target price of $5.50, indicating a potential upside of 3,135.29%. Given Tonix Pharmaceuticals' higher possible upside, analysts clearly believe Tonix Pharmaceuticals is more favorable than Celularity.
In the previous week, Tonix Pharmaceuticals had 1 more articles in the media than Celularity. MarketBeat recorded 5 mentions for Tonix Pharmaceuticals and 4 mentions for Celularity. Tonix Pharmaceuticals' average media sentiment score of 0.95 beat Celularity's score of 0.55 indicating that Tonix Pharmaceuticals is being referred to more favorably in the media.
Tonix Pharmaceuticals has a net margin of 0.00% compared to Celularity's net margin of -1,226.72%. Celularity's return on equity of 30.79% beat Tonix Pharmaceuticals' return on equity.
Tonix Pharmaceuticals received 331 more outperform votes than Celularity when rated by MarketBeat users. Likewise, 63.60% of users gave Tonix Pharmaceuticals an outperform vote while only 42.11% of users gave Celularity an outperform vote.
Summary
Tonix Pharmaceuticals beats Celularity on 9 of the 15 factors compared between the two stocks.
Get Tonix Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TNXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tonix Pharmaceuticals Competitors List
Related Companies and Tools
